|
Jan 4
|
Eli Lilly's (NYSE:LLY) Dividend Will Be Increased To $1.50
|
|
Jan 4
|
Prediction: These 3 Healthcare Stocks Will Soar in 2025
|
|
Jan 3
|
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
|
|
Jan 3
|
From Davids to Goliaths: the GLP-1RA gold rush
|
|
Jan 3
|
Eli Lilly Joins FDA Lawsuit Over Compounded Obesity Drugs, Seeks 'Swift End' And 'To Protect Its Interests'
|
|
Jan 3
|
The Zacks Analyst Blog Eli Lilly, J&J, AbbVie, AstraZeneca and Pfizer
|
|
Jan 2
|
Zepbound will dominate obesity market following SURMOUNT-5 results, says analyst
|
|
Jan 2
|
Eli Lilly Stock Upgraded to "Buy" as Analysts Boost Price Target to $1,250
|
|
Jan 2
|
US Employer Health Costs To Rise In 2025 Fueled By Weight Loss: Report
|
|
Jan 2
|
5 Large Drug Stocks to Keep An Eye On in the New Year
|
|
Jan 2
|
Should You Buy the Dip in Novo Nordisk Stock Right Now?
|
|
Jan 2
|
Tirzepatide outpacing Wegovy in the obesity space
|
|
Jan 2
|
Can Eli Lilly and Company (NYSE:LLY) Maintain Its Strong Returns?
|
|
Jan 2
|
Weight loss drugs are changing the game, Eli Lilly exec says — but many still can't get them
|
|
Jan 1
|
Jim Cramer’s Take on Eli Lilly and Company (LLY): Bold Predictions for the Future
|
|
Jan 1
|
Drug-Trial Results Could Shake Up Pharma Stocks in 2025. Watch Eli Lilly, Pfizer, and More.
|
|
Dec 31
|
GLP-1 questions emerge for 2025
|
|
Dec 31
|
Novo Nordisk A/S (NVO): A Bull Case Theory
|
|
Dec 31
|
Lilly and Novo Went Head-to-Head Over Weight-Loss Drugs in 2024. There’s a Clear Winner.
|
|
Oct 13
|
3 No-Brainer Growth Stocks to Buy in October
|